^
    CANCER:

    Diffuse Large B Cell Lymphoma





    Show legend
    Group by Gene:
    Include preclinical:

    CD19-targeted CAR-T immunotherapy
    lisocabtagene maraleucel
    axicabtagene ciloleucel
    		0
    CD19-targeted CAR-T immunotherapy
    tisagenlecleucel-T
    CB-010
    ALLO-501A
    relmacabtagene autoleucel
    JCAR014
    rituximab
    Rixathon (rituximab biosimilar)
    		1
    CD20 inhibitor
    rituximab / hyaluronidase
    rituximab-abbs
    rituximab-pvvr
    BTK inhibitor
    ibrutinib
    		2
    BTK inhibitor
    zanubrutinib
    orelabrutinib
    acalabrutinib
    JNJ-4681
    3
    DNA replication inhibitor, CD19-targeted antibody-drug conjugate
    loncastuximab tesirine-lpyl
    IKS03
    4
    PD1 inhibitor
    pembrolizumab
    5
    XPO1 inhibitor
    selinexor
    6
    PD1 inhibitor, BTK inhibitor
    nivolumab + ibrutinib
    tislelizumab + zanubrutinib
    7
    THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
    methotrexate
    8
    BTK inhibitor, CD20 inhibitor
    CD20 inhibitor + zanubrutinib
    rituximab + zanubrutinib
    9
    DNMT inhibitor
    azacitidine oral
    10
    PD1 inhibitor, LAG-3 inhibitor
    MGD013
    11
    SETD2 inhibitor
    IPN60210
    12
    PD1 inhibitor, Survivin inhibitor
    pembrolizumab + MVP-S
    13
    Topoisomerase II inhibitor
    pixantrone
    14
    Bcl2 inhibitor, CD20 inhibitor
    venetoclax + obinutuzumab
    15
    PD-L1 inhibitor
    atezolizumab
    tazemetostat
    		16
    EZH2 inhibitor
    CPI-169
    SHR-2554
    17
    BET inhibitor
    RG6146
    INCB57643
    18
    CD19-targeted CAR-T immunotherapy, BCMA-targeted CAR-T immunotherapy
    GC012F
    19
    Cereblon modulator, Pleiotropic pathway modifier
    CC-122
    20
    ALK inhibitor
    crizotinib
    21
    CD19-targeted CAR-T immunotherapy, BTK inhibitor
    acalabrutinib + axicabtagene ciloleucel
    R-CHOP
    C-RICE
    Pola-R-CHP
    R-CEOP
    R-CDOP
    R-CEPP
    R-GCVP
    R-ESHAP
    CEPP
    CEOP
    EPOCH-R
    R-DHAP
    		22
    Chemotherapy
    MINE
    GDP
    EPOCH
    ViPOR
    RICE
    ICE
    ESHAP
    GemOx
    R-GemOx
    MATRix
    DHAP
    DHAX
    R-GDP
    ZPR
    23
    T-lymphocyte cell therapy
    T-lymphocyte cell therapy
    24
    USP47 inhibitor
    USP47 inhibitor
    25
    Immunotherapy
    Immunotherapy
    26
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
    lenalidomide
    27
    CD30-targeted antibody-drug conjugate, Microtubule inhibitor
    brentuximab vedotin
    epcoritamab-bysp
    		28
    CD3 agonist, CD20 inhibitor
    glofitamab-gxbm
    EX103
    29
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, CD20 inhibitor
    rituximab + lenalidomide
    30
    Tubulin polymerization promoter, DNA synthesis inhibitor, CD20 inhibitor
    carboplatin + gemcitabine + rituximab
    31
    Tubulin polymerization promoter, DNA synthesis inhibitor
    carboplatin + gemcitabine
    32
    TNFα inhibitor, CD19 inhibitor, IL-12 inhibitor, IL-6 inhibitor
    lenalidomide + tafasitamab-cxix
    33
    CD79b-targeted antibody-drug conjugate, Microtubule inhibitor
    polatuzumab vedotin-piiq
    34
    CD79b-targeted antibody-drug conjugate, Microtubule inhibitor, CD20 inhibitor
    rituximab + polatuzumab vedotin-piiq
    35
    CD20-targeted CAR-T immunotherapy, CD19-targeted CAR-T immunotherapy
    IMPT-314
    36
    CD16 agonist, NK cell stimulant
    FT516
    37
    CD22-targeted antibody-drug conjugate, DNA replication inhibitor
    inotuzumab ozogamicin
    38
    HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    chidamide
    39
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    40
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, BTK inhibitor
    lenalidomide + zanubrutinib
    41
    CD19 inhibitor, CD3 agonist
    A-319
    42
    CD30-targeted antibody-drug conjugate, Microtubule inhibitor, CD20 inhibitor
    rituximab + brentuximab vedotin
    43
    TNFα inhibitor, IL-12 inhibitor, PD1 inhibitor, IL-6 inhibitor, CD20 inhibitor
    rituximab + lenalidomide + penpulimab
    44
    CD79b-targeted antibody-drug conjugate, Microtubule inhibitor, Bcl2 inhibitor
    venetoclax + polatuzumab vedotin-piiq
    45
    Proteasome inhibitor, Chemotherapy
    R-CHOP + bortezomib
    46
    TNFα inhibitor, IL-1β inhibitor, IL-10 stimulant, NK cell stimulant, IL-6 inhibitor
    pomalidomide
    47
    HDAC inhibitor, PI3K inhibitor
    CUDC-907
    48
    PD-L1 inhibitor, Bcl2 inhibitor, CD20 inhibitor
    venetoclax + atezolizumab + obinutuzumab
    49
    MALT1 protein inhibitor
    JNJ-6633
    ONO-7018
    50
    Bcl2 inhibitor, BTK inhibitor
    ibrutinib + APG-2575
    venetoclax + ibrutinib
    51
    MDM2 inhibitor, Bcl2 inhibitor
    APG-115 + APG-2575
    52
    Bcl2 inhibitor
    APG-2575
    venetoclax
    53
    PDK1 inhibitor, Bcl2 inhibitor
    venetoclax + VRx-510
    54
    BET inhibitor, EZH2 inhibitor
    CPI-169 + CPI-203
    55
    Kinase inhibitor
    EUD-GK-001
    56
    Lymphoid kinome inhibitor, Myeloid kinome inhibitor, BTK inhibitor, FLT3 inhibitor
    CG-806
    57
    Lymphoid kinome inhibitor, Bcl2 inhibitor, Myeloid kinome inhibitor, BTK inhibitor, FLT3 inhibitor
    venetoclax + CG-806
    58
    PIM inhibitor, Bcl2 inhibitor, BTK inhibitor
    venetoclax + ibrutinib + AZD1208
    59
    PLK4 inhibitor
    CFI-400945
    60
    EZH2 inhibitor, Bcl2 inhibitor
    venetoclax + tazemetostat
    61
    MCL1 inhibitor
    S63845
    62
    MCL1 inhibitor, Bcl2 inhibitor
    venetoclax + S63845
    63
    LRRK2 inhibitor, ALK inhibitor
    TAE-684
    64
    XPO1 inhibitor, Bcl2 inhibitor
    venetoclax + selinexor
    65
    ACVR1 inhibitor, IRAK-1 inhibitor, CSF-1R inhibitor, JAK2 inhibitor, FLT3 inhibitor
    pacritinib
    66
    BTK degrader
    ABBV-101
    67
    Bcl2 inhibitor, Tubulin inhibitor, CD20 inhibitor
    AR160
    68
    IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader, CD20 inhibitor
    rituximab + KT-413
    69
    MALT1 protein inhibitor, BTK inhibitor
    JNJ-6633 + JNJ-4681
    70
    Topoisomerase II inhibitor, HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    doxorubicin hydrochloride + chidamide
    71
    PARP inhibitor
    olaparib
    72
    Electron transport complex I inhibitor
    IACS-010759
    73
    Bcl2 inhibitor, SYK inhibitor
    venetoclax + fostamatinib
    74
    Histone acetyltransferase activator
    YF2
    75
    PIK3CA inhibitor, Bcl2 inhibitor, PI3Kδ inhibitor
    venetoclax + copanlisib
    76
    Apoptosis stimulant
    arsenic trioxide
    77
    miR-155 inhibitor
    MRG-106
    78
    Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor
    ABT 263
    79
    EIF-2 kinase modulator
    BTM-3566
    80
    HDAC1 inhibitor, HDAC2b inhibitor
    purinostat
    81
    THF dehydrogenase inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor
    cytarabine + methotrexate
    82
    HDAC inhibitor, EZH2 inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    chidamide + SHR-2554
    83
    PIK3CA inhibitor, PI3Kδ inhibitor
    copanlisib
    84
    CD20-targeted CAR-T immunotherapy, Bcl2 inhibitor
    CD20-targeted CAR-T immunotherapy + venetoclax
    85
    PI3Kγ inhibitor, DNA PK inhibitor, Bcl2 inhibitor, PI3Kδ inhibitor
    venetoclax + BR101801
    86
    EZH1 inhibitor, EZH2 inhibitor
    DW91170
    87
    IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader, BTK inhibitor
    BTK inhibitor + KT-413
    88
    IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader
    KT-413
    No biomarker
    MYC rearrangement + BCL2 rearrangement
    MYC overexpression + BCL2 overexpression
    BCL2 overexpression + MYC overexpression
    BCL2 expression + MYC expression
    MYC translocation + BCL2 translocation
    MYC positive + BCL2 positive
    MYC expression + BCL2 expression
    BCL2 rearrangement + MYC amplification
    MYC rearrangement + BCL6 rearrangement
    MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
    MYC translocation + BCL6 translocation
    MYC positive + BCL2 positive + BCL6 positive
    MYC translocation + BCL6 translocation + BCL2 translocation
    BCL2 positive
    MYC rearrangement
    BCL2 overexpression
    MYC positive
    MYC expression
    MYC mutation
    BCL2 expression
    MYC negative
    BCL2 rearrangement
    BCL2 mutation
    MYC overexpression
    BCL2 amplification
    CD20 positive
    CD20 negative
    CD20 overexpression
    TP53 mutation
    LDH elevation
    CD19 positive
    PD-L1 overexpression
    PD-L1 amplification
    CD19 underexpression
    TP53 deletion
    LDH-L
    PD-L1 expression
    CD19 expression
    CD19 mutation
    TP53 expression
    CD79B mutation
    BCL6 rearrangement
    CD79B mutation
    BCL6 positive
    BCL6 translocation
    MYD88 mutation
    TMB-H
    PIM1 overexpression
    ALK I1171N
    TNFRSF8 positive
    TMB-L
    TNFRSF8 expression
    PIM1 mutation
    ALK positive
    MYD88 L265P
    TNFA-L
    PD-L1 amplification + CD3D overexpression
    IFNG-L
    CD24 overexpression
    EZH2 mutation
    CD5 positive
    CREBBP mutation
    H1-4 overexpression
    PAX5 overexpression
    CD19 expression + TNFRSF17 expression
    NOTCH1 mutation
    FOXP1 overexpression
    PD-1 overexpression
    CDCA2 overexpression
    EP300 mutation
    CLTC-ALK fusion
    EZH2 mutation + BCL2 translocation
    CRTAM overexpression
    BCL6 fusion + NOTCH2 mutation
    SEPTIN6-TRIM33 fusion
    PD-L1 amplification + LAG3 overexpression
    PD-L1 amplification + HLA-DRA overexpression
    CD34 underexpression
    LRP1B mutation
    KLHL14 mutation
    LEF1 overexpression
    BTLA overexpression
    TIGIT overexpression
    CCND2 overexpression
    LAG3 overexpression
    SOCS1 mutation
    NPM1-NR4A3 fusion
    IKZF1 deletion + IKZF3 deletion
    CD79A mutation
    MYC amplification + BCL2 amplification + TNFRSF8 expression
    MYD88 L265P + CD79B mutation
    BIRC5 expression
    PAX5 mutation
    BCL2 fusion + EZH2 mutation
    EZH2 overexpression
    EZH2 Y641
    Chr t(2;17)(p23;q23) CLTC/ALK
    EP300 overexpression
    PD-1 elevation
    CD5 overexpression
    CD5 gene expression signature
    PLK4 expression
    BCL2L11 deletion
    IL2RA positive
    MCL1 expression
    MYC expression + PAICS expression
    miR-885-3p expression
    miR-199a-5p expression
    XPO1 E571K
    TP53 mutation + BCL2 rearrangement
    miR-193b-5p expression
    miR-6860-5p expression
    BTK C481S
    PDK4 overexpression
    BRCA mutation
    MYC expression + MCL1 expression
    FCGR2B expression
    VEGFA 1154G/A
    NOTCH2 mutation
    MDM2 amplification
    CDK2 amplification
    CDK4 amplification
    TERT amplification
    BTK expression + BCL2 expression
    BTK expression + BCL2 expression + MYC expression
    BTK expression + MYC expression
    CD58 mutation
    IRF8 mutation
    TBX21 overexpression
    CCDC86 expression + NPM1 expression
    IL6 elevation
    CXCL8 elevation
    CCL4 elevation
    IL27 elevation
    CCND1 expression
    AP2M1 overexpression
    BCL2 positive + LGALS3 expression
    REL overexpression
    Chr del(17p)
    CDKN2A deletion
    GNA13 mutation
    PRDM1 mutation
    CDKN2B deletion
    MYC rearrangement + LDH elevation
    IRF4 mutation
    B2M mutation
    MELK overexpression
    BACH2 overexpression
    SETD1B overexpression
    INO80 overexpression
    SETD2 overexpression
    KMT2C overexpression
    NCOR1 overexpression
    CHD8 overexpression
    ARID1B overexpression
    SETD5 overexpression
    SMARCA4 overexpression
    MAD2L2 overexpression
    PPM1D mutation
    LDH elevation + TP53 mutation
    KLHL6 expression
    IKZF1 G151A overexpression
    IKZF3 G152A overexpression
    BCL2L1 overexpression
    miR-182-5p expression
    Albumin-L
    TP53 overexpression + CD5 overexpression
    FTL elevation
    LMO2 overexpression
    miR-20b-5p expression
    miR-1231 expression
    PTPN6 negative
    KMT2D mutation
    PTEN deletion + BCL2 translocation
    miR-155 overexpression
    BCL2L2 overexpression
    CARD11 mutation
    CD79B mutation + TNFAIP3 mutation
    BCL2 overexpression + MCL1 overexpression
    BCL2 overexpression + MCL1 expression
    miR-1244 expression
    SRC overexpression
    JAK2 overexpression
    LCK overexpression
    miR-6840-3p expression
    miR-1244 overexpression + miR-193-5p overexpression
    LY9 expression